Crohn's disease is a disease with unknown etiology that can affect all departments of the intestine. Most often localized in the ileum of the small intestine. Crohn's disease is characterized by destruction of all layers of the intestinal wall, a strong inflammatory reaction, severe pain after eating.
Recently conducted two clinical trials have confirmed the effectiveness of modern tools Vedolizumab. The drug is distributed in vials for intravenous infusion and saves from the symptoms of Crohn's disease and ulcerative colitis: inflammation of the intestine, inhibits diarrhea, severe pain, bleeding in the gastrointestinal tract.
For testing were selected volunteers with Crohn's Disease and ulcerative colitis. The participants were United by one common factor - the standard therapy in the form of steroid hormones and immunodepressants they did not fit.
The subjects took the drug throughout the year. The first results were not long in coming: many felt improvement after six weeks, says Fox News. When the disease went into remission, patients were excluded from the list of medications prednisolone, hormonal drug with many side effects.
Vedolizumab was developed in the laboratory Takeda. The basic principle of drug action - blockade of cells involved in immune reactions. They, releasing proteins-cytokines, causing inflammatory autoimmune reaction, taking the native tissue of the intestine for a foreign agent with which you must contend. In the process of taking the drug relieves nausea, stomach pain, especially after eating, reconstruction of body weight. The only disadvantage of the drug is increasing the risk of infections.